Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Primary Sjögren's Syndrome
NCT02067910Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2014
- Primary completion
- Feb 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abatacept in primary Sjögren's syndrome, sponsored by University Medical Center Groningen. Primary endpoint: EULAR Sjögren's Syndrome Disease Activity Index at 24 weeks. Started Aug 2014; status: completed.
02
Drugs
abatacept
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT02067910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02067910.